• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Biomerica Inc.

    2/27/26 5:15:26 PM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $BMRA alert in real time by email
    S-8 1 forms-8.htm S-8

     

    As filed with the Securities and Exchange Commission on February 27, 2026

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    Under

    THE SECURITIES ACT OF 1933

     

    BIOMERICA, INC.

    (Exact name of Registrant as specified in its charter)

     

    Delaware   95-2645573
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)
         
    17571 Von Karman Avenue, Irvine, California   92614
    (Address of principal executive offices)   (Zip Code)

     

    BIOMERICA, INC.
    2024 STOCK INCENTIVE PLAN

    (Full title of the plan)

     

    Zackary Irani

    Chief Executive Officer

    Biomerica, Inc.

    17571 Von Karman Avenue

    Irvine, California 92614

    (Name and address of agent for service)

     

    (949) 645-2111

    (Telephone number, including area code, of agent for service)

     

    Copy to:

    Michael A. Hedge

    K&L Gates LLP

    1 Park Plaza, Twelfth Floor

    Irvine, CA 92614

    (949) 623-3519

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
           
    Non-accelerated filer ☒ Smaller reporting company ☒
           
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (this “Registration Statement”) is being filed by Biomerica, Inc., a Delaware corporation (the “Registrant” or “Company”), to register an additional 200,000 shares of the Registrant’s common stock, par value $0.08 per share (the “Common Stock”), issuable under the Registrant’s 2024 Stock Incentive Plan (the “Plan”), as a result of the stockholders of the Registrant approving an amendment to the Plan to increase the shares of the Common Stock available for issuance under the Plan on December 12, 2025 at the Registrant’s 2025 Annual Meeting of the Stockholders.

     

    The additional shares are of the same class as other securities relating to the Plan for which this Registration Statement incorporates by reference the contents of the Registration Statement on Form S-8, File No. 333-283991, filed by the Registrant with the U.S. Securities and Exchange Commission (the “Commission”) on December 20, 2024 (the “Prior Registration Statement”). In accordance with Instruction E of Form S-8, the content of the Prior Registration Statement is incorporated herein by reference and made a part of this Registration Statement.

     

     

     

     

    Item 8. Exhibits.

     

    Exhibit Number   Exhibit Description
    4.1   Amended and Restated Certificate of Incorporation of Registrant filed with the Secretary of State of Delaware on August 1, 2000 (incorporated by reference to Exhibit 3.8 filed with the Registrant’s Annual Report on Form 10-KSB for the fiscal year ended May 31, 2000).
    4.2   Amended and Restated Bylaws, as adopted on July 24, 2023 (incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K filed July 26, 2023).
    4.3   Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K filed April 16, 2025).
    4.4   Specimen Stock Certificate of Common Stock of Registrant (incorporated by reference to Exhibit 4.1 filed with Registrant’s Registration Statement on Form SB-2, Commission No. 333-87231 filed on September 16, 1999).
    5.1   Opinion of K&L Gates LLP.±
    23.1   Consent of Independent Registered Public Accounting Firm (Haskell & White LLP).±
    23.2   Consent of K&L Gates LLP (included in Exhibit 5.1).±
    24.1   Power of Attorney (included on the signature page of this registration statement).±
    99.1   Biomerica, Inc. 2024 Stock Incentive Plan (incorporated herein by reference to Exhibit A to the Registrant’s Definitive Proxy Statement filed with the Commission on September 30, 2024).
    99.2   First Amendment to Biomerica, Inc. 2024 Stock Incentive Plan (incorporated herein by reference to Exhibit A to the Registrant’s Definitive Proxy Statement filed with the Commission on October 20, 2025).
    107.1   Filling Fee Table.±

     

    ± Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Irvine, State of California, on February 27, 2026.

     

      BIOMERICA, INC.
       
      By: /s/ Zackary Irani
        Zackary Irani
        Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below hereby constitutes and appoints Zackary Irani and Gary Lu and each of them, individually, as his or her attorneys-in-fact, with full power and authority, including full power of substitution, for the undersigned to sign, in any and all capacities, any amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission and to do any and all acts and things for and in name of the undersigned which such attorneys-in-fact, or any of them, individually, may deem necessary or advisable to enable Biomerica, Inc. to comply with the Securities Act of 1933, as amended, and any rules, regulations, and requirements of the Securities and Exchange Commission, in connection with this Registration Statement, and does hereby ratify and confirm all that any of said attorneys-in-fact, or any of their substitutes, may do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the respective capacities and on the dates indicated below.

     

    Name   Title   Date
             
    /s/ Zackary S. Irani   Chief Executive Officer and Director   February 27, 2026
    Zackary S. Irani   (Principal Executive Officer)    
             
    /s/ Gary Lu, CPA   Chief Financial Officer   February 27, 2026
    Gary Lu   (Principal Financial and Accounting Officer)    
             
    /s/ Allen Barbieri   Director, Vice Chairman and Secretary   February 27, 2026
    Allen Barbieri        
             
    /s/ David Moatazedi   Director   February 27, 2026
    David Moatazedi        
             
    /s/ Gary Huff   Director   February 27, 2026
    Gary Huff        
             
    /s/ Eric Bing Chin, CPA   Director   February 27, 2026
    Eric Bing Chin, CPA        

     

     

     

    Get the next $BMRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BMRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BMRA
    SEC Filings

    View All

    SEC Form S-8 filed by Biomerica Inc.

    S-8 - BIOMERICA INC (0000073290) (Filer)

    2/27/26 5:15:26 PM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 10-Q filed by Biomerica Inc.

    10-Q - BIOMERICA INC (0000073290) (Filer)

    1/14/26 5:15:42 PM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Biomerica Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - BIOMERICA INC (0000073290) (Filer)

    12/16/25 8:19:33 AM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $BMRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy

    Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company's peer-reviewed randomized controlled trial.CMS Payment Rate: $300 national Medicare payment rate established, effective January 1, 2026.Physician Perspective: New interview with Gastroenterologist Dr. Dak Patel about inFoods IBS in clinical use now available at https://investors.biomerica.com/events-and-presentations/default.aspx IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), an innovator in diagnostic-guided therapy, today announced respo

    2/26/26 8:19:00 AM ET
    $BMRA
    $HSIC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical Specialities

    Vietnam Approves Biomerica's EZ Detect™ for Nationwide Distribution

    Approval Marks Biomerica's Strategic Entry into Southeast Asia's Rapidly Growing Healthcare MarketSimple, FDA-Cleared At-Home Test Detects an Early Warning Sign of Colorectal Cancer in Minutes IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global provider of advanced diagnostic solutions, announced that Vietnam's Hanoi Department of Health has officially approved the EZ Detect™ colorectal disease at-home screening test for sales and distribution throughout Vietnam. Biomerica is working with a major healthcare products distributor in Vietnam who will manage the sales and distribution of the product through pharmacies, hospitals, physician's offices, and

    2/18/26 8:19:00 AM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test

    CMS is the single largest payer for healthcare in the United States, with Medicare responsible for approximately 21% of total healthcare expenditure.The $300 rate will apply to claims approved and paid by Medicare with dates of service on or after January 1, 2026.Adults of Medicare age comprise over 20% of US adults and a substantial portion of patients with IBS symptoms, making Medicare a critical payer for inFoods® IBS. IRVINE, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global provider of advanced diagnostic solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its final pricing determination for the company's inFoo

    12/23/25 8:19:00 AM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $BMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chin Eric was granted 22,500 shares, increasing direct ownership by 225% to 32,500 units (SEC Form 4)

    4 - BIOMERICA INC (0000073290) (Issuer)

    1/28/26 5:40:25 PM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Financial Officer Lu Gary was granted 40,000 shares, increasing direct ownership by 206% to 59,375 units (SEC Form 4)

    4 - BIOMERICA INC (0000073290) (Issuer)

    12/31/25 5:10:08 PM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Executive Vice-Chairman Barbieri Allen was granted 30,000 shares, increasing direct ownership by 127% to 53,543 units (SEC Form 4)

    4 - BIOMERICA INC (0000073290) (Issuer)

    12/31/25 5:10:05 PM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $BMRA
    Leadership Updates

    Live Leadership Updates

    View All

    Gary Huff, Former CEO of LabCorp Diagnostics, Appointed to Biomerica Board of Directors

    Brings decades of leadership in laboratory testing, clinical diagnostics, payor strategy, and sales growth Extensive track record in commercializing advanced laboratory testing and insurer strategies IRVINE, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ:BMRA), a global provider of advanced diagnostic solutions, today announced the appointment of Gary Huff to its Board of Directors as an independent board member. Mr. Huff brings decades of leadership experience in the diagnostics and healthcare services industry, including serving as Chief Executive Officer of LabCorp Diagnostics, one of the world's largest clinical laboratories. Mr. Huff is a hands-on, inspirational,

    10/8/25 8:19:00 AM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Clinical Diagnostics Industry Leader Scott Madel Joins Biomerica's Team as Chief Commercial Officer

    Brings 20+ years of revenue growth leadership in laboratory testing, clinical diagnostics and global expansionLed successful organizational turnarounds and growth strategies at both Boston Heart Diagnostics and Genova DiagnosticsExtensive track record in commercializing advanced laboratory testing, driving growth and payer strategies IRVINE, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Scott Madel as Chief Commercial Officer. Scott brings more than two decades of cross-functional expertise in healthcare, diagnostics, commercialization, and pa

    6/26/25 8:19:00 AM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Biomerica Appoints Eric B. Chin to Board of Directors and Audit Committee Chair

    Mr. Chin brings over 20 years of financial experience across public and private healthcare organizationsMr. Chin currently serves as CFO of Akido Labs where he successfully helped raise $60 million in a recent financingMr. Chin's appointment strengthens Biomerica's corporate governance and financial oversight as Biomerica scales commercialization efforts IRVINE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products, today announced that Eric B. Chin has been appointed to the Company's Board of Directors, effective June 4, 2025. Mr. Chin will serve

    6/6/25 9:30:00 AM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $BMRA
    Financials

    Live finance-specific insights

    View All

    Biomerica Reports Financial Results for Fiscal 2023 Second Quarter Ended November 30, 2022

    InFoods® IBS Data Receives American College of Gastroenterology Presidential Award (ACG) Following Presentation at Annual Scientific Meeting  Trial Data Shows InFoods® IBS Treatment Diet Significantly Improved Several IBS Symptoms Including Abdominal Pain Intensity (API): In Some Cases Better Than Certain Currently Marketed Drugs  Launch of InFoods® IBS Lab Developed Test Expected in Fiscal 3Q  Amazon Now Fulfills Sales of Aware® Breast Self Exam and EZ Detect™ Colon Disease Tests IRVINE, Calif., Jan. 13, 2023 (GLOBE NEWSWIRE) -- IRVINE, CABiomerica, Inc. (NASDAQ:BMRA), (the "Company") a global provider of advanced medical products, today reported its second quarter fiscal 2023 fina

    1/13/23 6:39:00 PM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $BMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biomerica Inc.

    SC 13G/A - BIOMERICA INC (0000073290) (Subject)

    11/14/24 4:19:51 PM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Biomerica Inc. (Amendment)

    SC 13G/A - BIOMERICA INC (0000073290) (Subject)

    2/14/24 9:00:06 AM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Biomerica Inc.

    SC 13G - BIOMERICA INC (0000073290) (Subject)

    2/9/24 3:06:57 PM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care